Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

Pemphigoid is a family of rare autoimmune conditions that causes blistering and rashes on the skin and mucous membranes. The body mistakenly sends antibodies to bind to cells in the skin. These ...

Use of certain dipeptidyl peptidase 4 (DPP-4) inhibitors appears to be associated with a small but significantly elevated risk for developing the chronic blistering skin condition bullous pemphigoid, ...

Dupixent is the first and only targeted therapy to receive FDA approval for bullous pemphigoid. FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first ...

Dupilumab is now approved for bullous pemphigoid, showing efficacy in achieving sustained disease remission and reducing severity. The LIBERTY-BP ADEPT study demonstrated significant improvements in ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

Bullous pemphigoid is a rare autoimmune disease that affects your skin. It’s a chronic disease that causes itchy, fluid-filled blisters to form all over your body. Although people of all ages, ...

Bullous pemphigoid is an autoimmune disease that causes painful chronic blisters and welts. The condition is rare, and typically affects older adults. Sufferers' average age is 80 and usually already ...